Since its introduction in 1943 , penicillin has been the drug of choice in the treatment of gonorrhoea.
In recent years, however, the emergence of strains of N. gonorrhoeae with diminished sensitivity to penicillin makes it essential that reliable non-toxic alternatives to penicillin should be fully investigated.
In 1960, spectinomycin, a new broad-spectrum antibiotic product of Streptomyces spectabilis, was introduced as the sulphate salt by Messrs. Upjohn Ltd. (Mason, Dietz, and Smith, 1961) for use in genito-urinary tract infections. This preparation was found to be effective in treating gonorrhoea, the recommended dose of 2 g. for males and 3 g. for females giving cure rates of 87 to 95 and 92 per cent. respectively (Laird and Taylor, 1962; Wilcox, 1963 Of the 104 male patients starting the trial, three (2 9 per cent.) defaulted immediately after treatment, seven (6 7 per cent.) after 3 days (after the first test of cure), and one (1 per cent.) after the second test of cure. Of the remainder, a further eleven patients (10-5 per cent.) defaulted more than 2 weeks after treatment.
Spectinomycin in gonorrhoea 273
Five patients (4 8 per cent.) became re-infected at periods ranging from 3 days to 3 weeks. Three of these patients had had two negative tests of cure and two had had one negative test of cure. All five were asymptomatic before re-exposing themselves. 23 men (22-1 per cent.) developed post-gonococcal urethritis.
One male and one female patient had positive cultures for N. gonorrhoeae after treatment and were considered to be treatment failures (Table III) . However, the female patient subsequently responded to the same dosage of spectinomycin. After an intramuscular injection of 2 g. spectinomycin, serum levels reach on average 100 ,ug./ml.
(minimum 35 [xg./ml.) (Savage, 1972) .
Both figures are many times that required for the strains isolated.
SIDE-EFFECTS
All patients were questioned specifically about possible side-effects. No patient complained of the treatment being painful or uncomfortable. One patient had transient haematuria of uncertain cause.
Discussion
Because of the small number of women in this trial no conclusions can be drawn regarding the efficacy of spectinomycin in the treatment of females. In males the failure rate of 1 1 per cent. compares favourably with most other regimens for treating acute gonorrhoea. If one assumes that those patients who default have been cured, then the failure rate falls below 1 per cent. Such an assumption is not without justification in the present series when one considers the defaulters in more detail. Of the eleven male patients who defaulted before 2 weeks, one returned some 3 months after treatment (with an entirely unrelated complaint) saying, that as the discharge had cleared up he had not bothered to re-attend; another seven patients had one negative test of cure and one had two negative tests of cure.
The failure rate obtained in this trial is as low as that obtained by giving probenecid and 5 million units of benzyl penicillin. With this latter treatment, Gray, Phillips, and Nicol (1970) reported a failure rate as low as 0 5 per cent. in London; Thin (1973) obtained a failure rate of 1-3 per cent. in Singapore and of 1-7 per cent. in Edinburgh (Thin, 1974) . On the basis of low failure rate and relative freedom from side-effects, spectinomycin can be regarded as a suitable alternative to penicillin in the treatment of acute gonorrhoea.
Summary
Of 104 male and nine female patients with uncomplicated acute gonorrhoea who were treated with spectinomycin (males 2 g., females 4 g.), two patients (one male and one female) were considered to be treatment failures. No conclusions can be drawn from the small numbers of female patients investigated. Of the 104 male patients, 93 were followed for 2 weeks or more, giving a failure rate of 1 1 per cent. The drug was well tolerated. Sensitivity tests were carried out on 44 strains of N. gonorrhoeae; 42 strains were sensitive to 2-5 ,ug./ml. spectinomycin and all strains were sensitive to 5 .tg./ml.
